Linagliptin Recommended for Approval in the Treatment of Type 2 Diabetes in Europe | Business Wire
Links shared publicly online about this topic.
- 195total visits
Linagliptin Recommended for Approval in the Treatment of Type 2 Diabetes in Europe | Business Wire
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today received a positive opinion from the European Medicines Agency’s (EMA) medicinal
View full resource at businesswire.com
Tags: Diabetes, Type 2 Diabetes, Eli Lilly and Company, Boehringer Ingelheim, Medical
Most Recently Shared on June 24, 2011 at 2:45 pm By:
Linagliptin Recommended for Approval in the Treatment of Type 2 Diabetes in Europe: INGELHEIM, Germany--(BUSINES... http://bit.ly/jqrcRT
Trajenta® (linagliptin) Receives Approval for the Treatment of Type 2 Diabetes in Europe | Business Wire
businesswire.com — “Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today received Marketing Authorisation from the European Commission for Trajenta® (lina” View full resource at businesswire.com
Most Recently Shared on August 25, 2011 at 4:23 pm By:
Trajenta® (linagliptin) Receives Approval for the Treatment of Type 2 Diabetes in Europe: INGELHEIM, Germany--(B... http://t.co/q3iuowC
Advertisement
